Last reviewed · How we verify
Solifenacin with vaginal estrogen cream
Solifenacin blocks muscarinic receptors to reduce overactive bladder contractions, while vaginal estrogen cream restores local estrogen levels to improve vaginal atrophy and urogenital symptoms.
Solifenacin blocks muscarinic receptors to reduce overactive bladder contractions, while vaginal estrogen cream restores local estrogen levels to improve vaginal atrophy and urogenital symptoms. Used for Overactive bladder with urge incontinence in postmenopausal women, Urogenital atrophy and vaginal dryness associated with menopause.
At a glance
| Generic name | Solifenacin with vaginal estrogen cream |
|---|---|
| Also known as | Vesicare and Premarin, Premarin |
| Sponsor | Mackay Memorial Hospital |
| Drug class | Anticholinergic agent (solifenacin) + topical estrogen (vaginal cream) |
| Target | M3 muscarinic receptor (solifenacin); estrogen receptor (vaginal estrogen) |
| Modality | Small molecule |
| Therapeutic area | Urology / Gynecology |
| Phase | FDA-approved |
Mechanism of action
Solifenacin is an anticholinergic agent that inhibits M3 muscarinic receptors on bladder smooth muscle, decreasing involuntary contractions and urgency. Vaginal estrogen cream provides localized estrogen replacement to restore vaginal epithelial health, improve lubrication, and reduce urogenital atrophy symptoms. Together, they address both the neurogenic and hormonal components of overactive bladder and urogenital dysfunction in postmenopausal women.
Approved indications
- Overactive bladder with urge incontinence in postmenopausal women
- Urogenital atrophy and vaginal dryness associated with menopause
Common side effects
- Dry mouth
- Constipation
- Blurred vision
- Urinary retention
- Vaginal irritation or spotting (from estrogen cream)
Key clinical trials
- Efficacy of Combined Pharmacotherapy Versus Solifenacin With Vaginal Estrogen Cream for Women With Detrusor Overactivity (PHASE4)
- Efficacy of Solifenacin or Mirabegron With Local Estrogen Versus Combination Pharmacotherapy for Overactive Bladder (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: